Vaccines comprising mutant attenuated influenza viruses
The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain.
1. A vaccine comprising an effective amount of a live, attenuated isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein comprising an extracellular domain or a portion thereof, a deletion of a cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain,
wherein (a) the mutant M2 protein further comprises a heterologous protein at the C-terminus of the extracellular domain, (b) the mutant M2 protein further comprises a heterologous immunogenic protein of a pathogen, (c) the recombinant influenza virus comprises a hemagglutinin (HA) that is modified at the HA cleavage site, (d) the recombinant influenza virus further comprises another attenuating mutation, (e) the recombinant influenza virus comprises a HA that is a heterologous HA, or (f) the recombinant influenza virus comprises a neuraminidase (NA) that is a heterologous NA.
2. The vaccine of claim 1 wherein the mutant M2 protein consists of the M2 extracellular domain.
3. The vaccine of claim 1 wherein the M2 extracellular domain or the portion thereof comprises less than 24 residues.
4. The vaccine of claim 1 wherein the portion of the M2 extracellular domain comprises at least 9 residues.
5. The vaccine of claim 1 wherein the mutation in the transmembrane domain comprises at least one amino acid substitution.
6. The vaccine of claim 1 wherein the mutation in the transmembrane domain comprises a deletion in the transmembrane domain.
7. The vaccine of claim 1 wherein the recombinant influenza virus comprises influenza A HA.
8. The vaccine of claim 7 wherein the HA in the recombinant virus is modified at the HA cleavage site.
9. The vaccine of claim 1 wherein the recombinant influenza virus further comprises another attenuating mutation.
10. The vaccine of claim 1 that is formulated for intranasal delivery.
11. The vaccine of claim 1 wherein the amount of the attenuated virus in the vaccine is 10 3 to 10 7 PFU/kg.
12. A method to immunize a vertebrate, comprising:
administering to the vertebrate an effective amount of the vaccine of claim 1 .
13. The method of claim 12 wherein the vertebrate is a human.
14. The method of claim 12 wherein the recombinant influenza virus has a HA that is H5 or H1.
15. The method of claim 12 wherein the vaccine is intranasally administered.
16. A method of making a dose of a vaccine, comprising:
providing a composition comprising live, attenuated isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain; and dispensing a portion of the composition into a receptacle in an amount of the live, attenuated isolated recombinant influenza virus effective to induce a protective immune response in a human.
17. The method of claim 16 wherein the HA in the attenuated isolated recombinant influenza virus comprises H5 HA.
18. The method of claim 16 wherein the receptacle further comprises at least two influenza viruses that are different from the attenuated isolated recombinant influenza virus.
19. The method of claim 16 wherein the attenuated isolated recombinant influenza virus is a reassortant virus.
20. The method of claim 16 wherein the amount is effective for intranasal delivery in a human.
21. The vaccine of claim 1 wherein the mutant M2 protein further comprises the heterologous protein at the C terminus of the extracellular domain.
22. The vaccine of claim 1 wherein the mutant M2 protein comprises the heterologous immunogenic protein of a pathogen.
23. The vaccine of claim 1 wherein the recombinant influenza virus comprises the heterologous HA.
24. The vaccine of claim 1 wherein the recombinant influenza virus comprises the heterologous NA.
25. The vaccine of claim 1 wherein the recombinant influenza virus comprises the heterologous HA and the heterologous NA.
26. The method of claim 16 wherein (a) the mutant M2 protein further comprises a heterologous protein at the C-terminus of the extracellular domain, (b) the mutant M2 protein further comprises a heterologous immunogenic protein of a pathogen, (c) the recombinant influenza virus comprises a hemagglutinin (HA) that is modified at the HA cleavage site, (d) the recombinant influenza virus further comprises another attenuating mutation, (e) the recombinant influenza virus comprises a HA that is a heterologous HA, or (f) the recombinant influenza virus comprises a neuraminidase (NA) that is a heterologous NA.